RFL Rafael Holdings Inc Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

$50.41  +1.05 (2.13%)
As of 07/28/2021 16:00:02 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Real Estate
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/27/2018
Outstanding shares:  16,927,318
Average volume:  102,548
Market cap:   $841,795,524
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75062E106
ISIN:        US75062E1064
Sedol:      BFWZ8G9
Valuation   (See tab for details)
PE ratio:   -42.35
PB ratio:   6.53
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy